The pI6-pRb pathway represents a vital cell-cycle checkpoint. In the present study we investigated the alterations of this GI-phase protein pathway using immunohistochemical and molecular methods in a series of 55 breast carcinomas and correlated the findings with clinicopathological features of the patients. Furthermore, we examined its relationship with the status of the chromosomal region 9p21-22 performing a deletion map analysis because there are indications that, in addition to CDKN2 and MTS2/ pJ5 INK4B tumor suppressor genes (TSGs), this area harbors other TSG(s).
Abstract
The pI6-pRb pathway represents a vital cell-cycle checkpoint. In the present study we investigated the alterations of this GI-phase protein pathway using immunohistochemical and molecular methods in a series of 55 breast carcinomas and correlated the findings with clinicopathological features of the patients. Furthermore, we examined its relationship with the status of the chromosomal region 9p21-22 performing a deletion map analysis because there are indications that, in addition to CDKN2 and MTS2/ pJ5 INK4B tumor suppressor genes (TSGs), this area harbors other TSG(s).
Aberrant expression (Ab) of p16 and pRb was observed in 26 (47%) and 16 (29%) of the carcinomas, respectively. A statistical trend pointing out an inverse relationship between p 16 and pRb expression was found (p = 0.079). Analysis of the region that encodes for p16 by deletion mapping, a PCR-based methylation assay and PCR-SSCP, revealed that deletions and transcriptional silencing by methylation might represent the main mechanisms of CDKN2/pJ6INK4A inactivation in breast carcinomas. The results of deletion mapping also suggest that another TSG(s) may reside at the 9p21-22 area particularly at the D9S162 loci and that co-deletion of this putative gene with CDKN2/p16INK4A may play a role in breast carcinogenesis. In addition, microsatellite instability (MI), a marker of replication error phenotype (RER+), was observed with a frequency of 16% in the area examined and was inversely related with loss of heterozygosity (LOH). Interestingly, most cases with MI at the region encoding for p16 were aggregated in a subgroup of breast carcinomas with no other obvious genetic and/or epigenetic CDKN2/pljNIC4A alterations. We speculate that there is an additional mechanism of CDKN2/p6INK4A inactivation. The relationship of p16 protein level pRb, status, the p1 6-pRb combined immunoprofiles, and the microsatellite alterations detected at the 9p21-22 locus with the patients' clinicopathological parameters revealed two significant correlations: one between normal pRb expression and lymph node involvement (p = 0.0263), and the other between microsatellite alterations (LOH and or MI) and tumor size (p = 9.2 X Introduction Breast carcinoma is the most common malignant tumor and the second cause of carcinoma death after lung cancer in women (1) . Recently, apart from genetic factors, hormonal imbalances, and environmental parameters considered to be implicated in breast cancer development, more has been learned of the possible implications of oncogenes and oncosuppressor genes (2) . It is not surprising that alterations in the molecular machinery controlling the transition from GI to S phase might represent central events leading to breast cancer generation. In this respect, there is a strong body of evidence that cell-cycle regula-tors are involved in human cancer development (3) .
Ongoing studies in this field revealed the p 16 product of CDKN2 gene is an important molecule involved in controlling cell-cycle progression. The CDKN2 gene has been mapped to chromosome region 9p21 and produces two transcripts (a and b) encoding two different proteins, p16INK4a and p9ARF, respectively. P1 INK4a , an 156-amino acids (aa) protein with a molecular weight of p16kDa, functions as an inhibitor of cyclin-dependent kinase 4/6 (CDKs 4/6) (4,6). Retinoblastoma protein (pRb) phosphorylation by CDKs 4/6 is a critical step in cell cycle progression. The pRb protein (pI09RB1) consists of 928aa, has a molecular weight of 105kDa, and is encoded by RB1 tumor suppresser gene which is located on chromosome region 13qI4.2 (reviewed in 7). Uncontrolled phosphorylation of pRb by CDKs 4/6 due, either to loss of functional p16 or cyclin-DI overexpression, may lead to irregular cellular proliferation (3) . The CDKN2/ INK4a gene product seems to be a candidate tumor suppresser protein as it has been found to be non-functional in a high percentage of cell lines and various malignancies (3, 8, 9) . Genetic alterations, including homozygous deletions, mutations, loss of one allele and inactivation of the other probably due to hypermethylation, appear to consist the most common mechanisms led to non-functional pI6INK4a (2, 6, 7) . A difference in the frequency of CDKN2 genetic alterations between cell lines and primary tumors may be caused by contamination of cancerous tissue with material derived from the surrounding stromal cells and artifactual or cellular adaptation during cell culture (9) (10) (11) (12) . A similar explanation has been given for discrepancies found in pRb studies (13) . In a wide spectrum of malignancies such as retinoblastomas, small cell lung carcinoma, bladder, pancreatic and breast carcinomas, pRb was inactivated by mutations (reviewed in ref. 7) . Investigation of pRb and p16 protein expression at the single cell level by immunohistochemistry could be the answer to the problem of evaluating the pRb and p16 alterations using conventional molecular biology methods.
Controversy continues to surround the frequency and mechanisms of CDKN2 gene inactivation in primary breast carcinomas (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . In reviewing the world literature published so far, we found four reports dealing with aberrant p16 immunoexpression and in situ distribution with percentages ranging from 37% to 73% (14) (15) (16) (17) 24) . Although most studies agree that point mutations represent a rather rare mechanism of CDKN2 inactivation (0 -5/o) (18, (20) (21) (22) (23) 25) , there is great discrepancy regarding CDKN2 gene deletion, with figures varying from 0% to 58% (20) (21) (22) (23) 25, 26) . In addition, only two reports deal with the methylation status of the CDKN2 gene in breast cancer, and they report contradicting findings (19, 27) . A similar discordance seems to exist concerning pRb inactivation in breast carcinomas (7-47%/) (14, (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) .
It has been postulated that the p16-pRb pathway is regulated by a feedback loop involving pRb (39, 40) . In such a case, deregulated expression of pRb, by hyperphosphorylation, mutation, or association with viral oncoproteins, would permit high levels of p1 6. The existence of this inverse relationship in breast carcinomas is not clear yet (14, 17, 24) .
The goals of the present study were to investigate the expression of p16 and pRb and their interrelationship in a series of 55 surgically resected sporadic invasive breast carcinomas; to correlate the findings with clinicopathological parameters and the hormonal status of the patients; and to look into the mechanisms of pJ6JNK4A inactivation. Finally, we sought to examine the state of the chromosomal region 9p21-22 because there are indications that, in addition to CDKN2, MTS2/p151NK4B, and methylthioadenosine phosphorylase (MTAP) tumorsuppressor genes (TSGs), it harbors another TSG(s) (26, 41, 42) .
Materials and Methods

Tissue Samples
Specimens from 55 breast carcinomas (collected between November 1995 and December 1996) were obtained in less than 15 min after surgery. Two samples of each tumor were taken; one was snap-frozen in liquid nitrogen and stored at -700C, the other was formalin-fixed and paraffin-embedded (FFPE) . In addition, adjacent normal tissue was included from each specimen examined. The material comprised 48 ductal, 4 Lysis was carried out in a 55°C water bath for 48 hr. Additional proteinase K (50 ,ug/ml) was added on each day of lysis. DNA was extracted from the supernatant using the phenol:chloroform:isoamylalcohol method (49) .
Microsatellite Alteration Analysis of Chromosomnal Region 9p21-22 METHOD. DNA from normal and cancerous tissue was amplified by polymerase chain reaction (PCR) using a tight cluster of highly polymorphic microsatellite markers spanning 11 cM across 9p21-22 with the following order from telomeric 9p to centromeric 9p ( METHOD. Single-strand conformation analysis was performed on normal and tumor tissuederived DNA as previously described (52 Microsatellite Alteration Analysis of Chromosomal Region 9p21-22 For microsatellite analysis (MA) analysis we used a tight cluster of highly polymorphic microsatellite markers spanning 1 1 cM across 9p21-22 with the following order from telomeric 9p to centromeric 9p (Fig. 1A) : D9S162, IFNA, D9S171, and D9S126 (Fig. IA) .
Out of 55 cases, 47 (85%) were informative for D9S162, 49 (89%) for IFNA, 45 (82%) for D9S171, and 39 (71%) for D9S126. Thirteen (24%) breast carcinomas displayed loss of heterozygosity (LOH) in one or more markers (Fig. 4A) . The deletion frequencies for each antibody (see Materials and Methods) and hematoxylin counterstain (X 500). Fig. 3 . Ductal breast carcinoma with heterogenous aberrant pRb expression (the area with pRb normal expression is indicated with an arrowhead whereas the absence of pRb expression is indicated by an arrow). Streptavidin-biotin peroxidase technique with Rb 1 anti-pRb antibody (see Materials and Methods) and hematoxylin counterstain (X500).
marker are presented in Figure lB . The results were further categorized into three groups. Group LOH(c), the cases demonstrating a central LOH at the IFNA and/or D9S1 71 loci, indicating a possible deletion of the CDKN2 gene; group LOH(f), the patients with chromosomal abnormalities at the flanks upstream of IFNA and/or downstream of D9S1 71; and group LOH(-), the cases with no indication of LOH and/or noninformative (NI) samples. Seven of the 55 patients were placed in group LOH(c), 1 in group LOH(f), 5 in both groups: LOH(c) and LOH(f), and 42 in group LOH(-) ( Table 1) .
Apart from chromosomal deletions, 9 (16%) patients demonstrated MAs, which appeared as an expansion or a compression of a single or In relation to clinicopathological parameters, we observed a highly significant association between MAs and tumor size (p = 9.2 X 10-3) and a probably significant correlation between MI and tumor size (p = 0.0526) ( Table 3 ).
CDKN2/p16INK4A Gene Methylation Analysis
To address further the molecular basis of aberrant p16 expression, we examined the methylation status of CDKN2/pl6INK4A exon la, which has been shown to correlate strongly with transcriptional silencing of the gene (54). We found that 11 (20%) of the 55 carcinomas analyzed exhibited de novo methylation of exon la (Fig. 4C) (55, 56) . This can be explained by the findings that levels of p16 may vary as much as 5-fold during a cell cycle, the lowest occuring in GO and early GI phase (55) . A similar situation has been described in pRb levels (56) . In our study, sole cytoplasmic reactivity of p16 was disregarded. Its significance is unclear and has been observed by others (17) . Interestingly, in a recent study, Marsh and Varley reported exclusive cytoplasmic p16 expression in 21 out of 41 (51%) breast lesions (24) . Nevertheless, if cytoplasmic reactivity proves to be specific, one possible explanation for this could be that alteration in subcellular localization could represent an additional mechanism of p16 inactivation. Wild-type p53 protein has an analogous mechanism of loss of function (57) . Aberrant p16 was observed in 47% of the carcinomas. This is consistent with the findings of Gerardts and Wilson, who observed abnormal p16 protein staining in 49% of the breast carcinomas studied (16), while others have reported percentages ranging from 37% to 73% (14, 15, 17, 24) . This discrepancy may be due to technical parameters of the assays and/or criteria of positivity. Furthermore, assessment of p16, as well as pRb, in breast tissue is challenging because the latter is hard to cut and process in pathology laboratories, thus leading frequently to prolonged fixation, which is responsible for "antigen loss." P16 protein appears to be particularly susceptible to fixation solutions and this may explain the inconclusive staining results observed by us and others (16) .
To investigate the mechanisms that underlie p16INK4A inactivation, we examined the chromo- (20-23, 25,26) . In the present study LOH was observed in 24% of the samples, which is lower with the findings presented by the other groups (22, 26) and comparable to the percentage of LOH(c) (22%). Despite the low frequency of losses flanking the CDKN2/pJ 6INK4A area (11% at D9S162 and 5% at D9S126), 83% of them were accompanied by LOH(c). The D9S162 and D9S126 loci are placed 6 cM and 1 cM away from IFNA and D9S1 71, respectively, and have been proposed to lie near the location of putative TSG(s) (41, 60, 61) . The talin gene has recently been mapped in this region (62) and its product is a critical molecule for the formation of focal adhesions. Inactivation of talin disassembles many of these structures (63 (68, 69) and tetranucleotide repeats (71) . More studies are needed to clarify whether these variations in susceptibility of microsatellite sequences reflect the involvement of different mutated MMR genes, different mechanisms for generating MI, or simply differences in experimental design.
Abnormal loss of pRb expression was found in 29% of our cases, which is in accordance with the reported incidence of other series (14, (32) (33) (34) (35) 37 (14) . Alternatively, p16 may participate in other unknown pRb-independent pathways. This assumption can be sustained by the finding that p16 inactivation causes stimulation of cyclin D2 and D3, which may act on other substrates besides pRb (81) .
The relation between p1 6 status, pRb protein level, the pI6-pRb immunophenotypes, and the alterations detected at the 9p21-22 locus with the patients' clinicopathological parameters revealed only two significant correlations: one between positive pRb reaction and lymph node involvement (p = 0.026), and the other between microsatellite alterations and tumor size (p = 9.2 X 10-3). Our (34) . No (14, 37) , positive lymph node status (36) , and increased proliferative activity (35) . With respect to the relation between RB1 alterations and survival in breast cancer, the few published studies have shown no association. From these contrasting data, it is difficult to draw a specific picture of the role of the RB1 gene in sporadic breast cancer. The conflicting results could be due to the variety of techniques used to estimate RB1 status and expression. The accuracy of molecular studies may be affected by normal tissue "contamination", while immunohistochemistry has the advantage of evaluating protein expression at the single-cell level. However, in the case of pRb, immunohistochemistry gives no indication of the protein's phosphorylation status and therefore, of its activity state, nor does it distinguish mutant from wild-type pRb proteins. Hence, it is possible that this could be the case in certain samples of our study. With regard to our second significant finding, there has been no previous report of a correlation between microsatellite alterations at the 9p21-22 chromosomal region and a poor prognostic indicator, such as tumor size. Interestingly, we also observed a probably significant association between MI and tumor size (p = 0.05), which is in keeping with the work of Paulson et al., who demonstrated a correlation with factors commonly related to poor prognosis (71) . But this finding contrasts with other studies suggesting that MI is an early event in mammary tumorigenesis (68, 70) . Finally, the data concerning the relation between p16 and prognostic features are few (14, 15) . Dublin et al. unexpectedly found a strong association between p16-positive staining and poor prognosis (14) , while Ito et al. reported that abnormal p16 immunoreactivity was more frequent in tumors of larger size and/or higher stage (1 5) .
In view of the heterogenous nature of breast cancer, the large number of genetic targets recognized, and the overlapping and compensatory pathways linking most of them, we suggest that in a significant proportion of breast carcinomas, deregulation of the p16-pRb pathway in association with other unidentified TSG(s) of the 9p21-22 region may play a role in initiating or advancing the oncogenic procedure, whereas in other subgroups, alternative molecules may play this role.
